Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Evolus, Inc. (EOLS) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/09/2023 8-K Quarterly results
Docs: "Evolus Reports First Quarter 2023 Results and Provides Business Update",
"Evolus Announces Expansion into U.S. Dermal Filler Market with EvolysseTM, a First-Generation Cold Technology HA by Symatese"
03/08/2023 8-K Quarterly results
Docs: "Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update"
11/08/2022 8-K Quarterly results
08/02/2022 8-K Quarterly results
Docs: "Evolus Reports Second Quarter 2022 Results and Provides Business Update"
05/10/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
11/02/2021 8-K Quarterly results
Docs: "Evolus Reports Third Quarter 2021 Results and Provides Business Update"
08/04/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
10/29/2020 8-K Quarterly results
Docs: "Evolus Reports Third Quarter 2020 Results and Provides Business Update Q3 2020 Net Revenue of $17.7 Million&#59; 34 Percent Increase Over Q3 2019"
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
Docs: "Evolus Reports First Quarter 2020 Results and Provides Business Update"
02/25/2020 8-K Quarterly results
11/04/2019 8-K Quarterly results
08/12/2019 8-K Quarterly results
04/30/2019 8-K Quarterly results
Docs: "Evolus Reports First Quarter 2019 Financial Results U.S. Sales Force Hired and Trained with U.S Launch of Jeuveau™ Imminent"
03/18/2019 8-K Quarterly results
Docs: "Evolus Secures $100 Million Senior Debt Facility with Oxford Finance LLC Provides Non-Dilutive Financing and Increased Flexibility Ahead of Jeuveau™ U.S. Launch",
"Evolus Reports Fourth Quarter and Full Year 2018 Results Received U.S. FDA Approval of Jeuveau™ on February 1, 2019 Majority of Sales Force Hired with Launch Planned in the Coming Weeks Hosting Investor & Analyst Day on May 8th , 2019 in"
11/05/2018 8-K Quarterly results
Docs: "Evolus Reports Third Quarter 2018 Financial Results - Within 90 Days of FDA PDUFA Action Date for DWP-450 - - Granted Marketing Approval for DWP-450 by Health Canada - - Conference Call Today at 4:30PM ET -"
08/02/2018 8-K Quarterly results
Docs: "Evolus Reports Second Quarter 2018 Financial Results",
"Evolus Announces Early Resubmission to the FDA of its Biologics License Application for DWP-450"
03/29/2018 8-K Quarterly results
Docs: "Evolus Reports Fourth Quarter and Full Year 2017 Financial Results Irvine, Calif., March 29, 2018 – Evolus, Inc. , a medical aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today reported financial results for the fourth quarter and full year ended December 31, 2017. 2017 and Recent Business Highlights:"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy